List of Excipients in Branded Drug IBSRELA

IBSRELA Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

IBSRELA, the brand name for tenapanor, is a locally acting oral therapy for irritable bowel syndrome with constipation, or IBS-C. The commercial opportunity is concentrated in differentiated oral dosage forms, improved tolerability, pediatric and geriatric administration, international expansion, and generic-entry barriers. The current formulation is a conventional film-coated tablet containing lactose, microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, povidone, magnesium stearate, sodium lauryl sulfate, and colloidal silicon dioxide. Its excipient estate is likely less defensible than the underlying tenapanor composition, method-of-use, and formulation patents.

IBSRELA was approved by the U.S. Food and Drug Administration in September 2019. The recommended adult dose is 50 mg twice daily, taken immediately before breakfast or the first meal of the day and dinner. A 25 mg twice-daily dose is available for patients who do not tolerate the 50 mg dose.[1]

What is IBSRELA and how does its formulation work?

IBSRELA contains tenapanor, a small-molecule inhibitor of the sodium/hydrogen exchanger 3, or NHE3, in the intestinal epithelium. Tenapanor reduces sodium absorption in the gut, increases intestinal water content, and accelerates bowel transit. The drug has low systemic exposure and acts primarily in the gastrointestinal tract.[1]

The dosage form is an immediate-release, film-coated tablet. The label directs patients to swallow the tablet whole. The product is not labeled for crushing, chewing, or dispersing in food or liquid.[1]

IBSRELA composition and inactive ingredients

The FDA-approved product uses a conventional direct-compression or wet-granulation-style tablet platform, based on the listed inactive ingredients:

Formulation component	Listed or likely function
Lactose monohydrate	Diluent and tablet-volume builder
Microcrystalline cellulose	Compression aid and diluent
Crospovidone	Superdisintegrant
Hydroxypropyl cellulose	Binder
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting agent and dissolution aid
Colloidal silicon dioxide	Glidant and flow aid
Film-coating materials	Color, protection, swallowability, and product identification

The excipient system is commercially familiar. It does not depend on a highly specialized lipid, polymer, enteric coating, or controlled-release technology. That lowers manufacturing complexity but creates room for competitors to pursue alternative formulations.

What excipient strategy is used in IBSRELA?

The current excipient strategy prioritizes rapid tablet disintegration, acceptable dissolution, manufacturability, and low-cost scale-up. That approach is appropriate for a locally acting gastrointestinal drug that does not require systemic exposure control.

Rapid disintegration and local intestinal action

Crospovidone, sodium lauryl sulfate, and the cellulose-based excipients support tablet wetting and breakup. Rapid disintegration may help expose tenapanor to the gastrointestinal lumen soon after administration.

The formulation does not need to protect tenapanor from absorption through a prolonged-release mechanism. Its pharmacology is based on intestinal exposure, making a conventional immediate-release tablet commercially efficient.

Manufacturing robustness

Microcrystalline cellulose, lactose, povidone, hydroxypropyl cellulose, magnesium stearate, and colloidal silicon dioxide are widely used excipients with established supply chains. Manufacturers can generally source these materials from multiple qualified suppliers, reducing dependence on a single excipient vendor.

The principal manufacturing risks are likely to involve:

• Blend uniformity at the relatively low active-ingredient load.
• Content uniformity between the 25 mg and 50 mg strengths.
• Lubrication sensitivity caused by magnesium stearate.
• Dissolution changes caused by particle-size variation or altered sodium lauryl sulfate levels.
• Film-coat performance and tablet identification.
• Stability under moisture and temperature stress.

Excipient tolerability

IBS-C patients often have gastrointestinal sensitivity. Excipients that can cause bloating, intolerance, or altered bowel symptoms may affect persistence even when the active ingredient is effective.

Potential commercial differentiators include:

• Lactose-free tablets.
• Reduced or eliminated sodium lauryl sulfate.
• Lower excipient mass.
• Reduced tablet size.
• Alternative binders for patients with excipient sensitivities.
• Improved taste or swallowability for older adults.
• Packaging that limits moisture exposure.

These changes would require comparative pharmaceutical development and regulatory support. They would not automatically create clinical differentiation.

What formulations are protected by IBSRELA patents?

The strongest protection for IBSRELA is expected to arise from the tenapanor molecule, pharmaceutical compositions, treatment methods, and specific formulations rather than from standard excipients individually.

Patent scope can include:

1. Tenapanor chemical composition and salts.
2. Use of tenapanor for IBS-C.
3. Use of tenapanor for constipation and related gastrointestinal disorders.
4. Pharmaceutical compositions containing tenapanor.
5. Dose regimens, including twice-daily administration.
6. Formulations that control dissolution, local intestinal exposure, or stability.
7. Combination treatment or patient-selection methods.

The exact enforceability of each claim depends on claim language, prosecution history, terminal disclaimers, patent-term adjustment, validity challenges, and Orange Book status. Standard excipients such as lactose, microcrystalline cellulose, povidone, and magnesium stearate are unlikely to provide meaningful standalone exclusivity. A patent directed to a specific ratio, process, coating, particle-size distribution, or dissolution profile could be more commercially relevant.

Can an excipient substitution avoid IBSRELA patent claims?

Potentially, but substitution alone does not eliminate all patent risk. A generic manufacturer must assess:

• The active-ingredient claims.
• Composition claims covering broad excipient classes.
• Formulation claims covering dissolution or tablet properties.
• Method-of-use claims.
• Manufacturing-process claims.
• FDA requirements for pharmaceutical equivalence and bioequivalence.
• The scope of any Paragraph IV certification.

A lactose-free tablet could avoid a narrow lactose-containing composition claim, but it would not avoid a claim covering tenapanor tablets broadly. An alternative disintegrant could also remain within a broad composition claim.

When does IBSRELA lose exclusivity?

IBSRELA's five-year new chemical entity exclusivity began with the September 2019 approval and generally expired in September 2024. NCE exclusivity prevents the FDA from accepting an abbreviated new drug application, or ANDA, for the same active ingredient during the exclusivity period, subject to the statutory framework.[2]

Patent expiry is separate from regulatory exclusivity. The commercial generic-entry date depends on the latest enforceable patent that covers the product or approved use, any patent-term adjustment or extension, litigation outcomes, and settlement terms.

Milestone	IBSRELA status
FDA approval	September 2019
NCE exclusivity	Generally expired in September 2024
Approved product	Tenapanor tablets, 25 mg and 50 mg
Approved indication	IBS-C in adults
Generic pathway	ANDA under Section 505(j)
Biosimilar pathway	Not applicable
Orange Book relevance	Listed patents and regulatory exclusivities determine entry constraints
Commercial entry risk	Increases after NCE expiry, subject to remaining patents and litigation

The FDA Orange Book is the controlling source for listed patent numbers, patent use codes, and regulatory exclusivity data.[3] Patent-term analysis should use the current Orange Book entry together with USPTO records and any federal court or Patent Trial and Appeal Board proceedings.

What is the Orange Book status of IBSRELA?

IBSRELA is a small-molecule drug, so its relevant FDA pathway is the ANDA pathway rather than the biosimilar pathway. The Orange Book may include patents covering the active ingredient, drug product, or approved method of use.

A Paragraph IV ANDA applicant can challenge listed patents by certifying that a patent is invalid, unenforceable, or will not be infringed by the proposed generic. The first substantially complete Paragraph IV filing may qualify for 180 days of generic exclusivity if statutory requirements are met.

The commercial significance of an IBSRELA Paragraph IV challenge would depend on:

• Whether the challenged patent is the last blocking patent.
• Whether the patent covers the active ingredient or only a narrower formulation.
• Whether Ardelyx files suit within 45 days.
• Whether a 30-month stay applies.
• Whether the parties settle.
• Whether the generic applicant has a first-filer position.
• Whether the proposed generic label carves out patented uses.

Which companies are challenging IBSRELA?

Publicly verified ANDA applicants, Paragraph IV notices, litigation complaints, and settlement terms should be tracked through FDA records, federal court dockets, and company SEC filings. A generic applicant may remain undisclosed until litigation, FDA approval, or a company disclosure.

No biosimilar challenge is relevant because tenapanor is a chemically synthesized small molecule rather than a biologic. The competitive threat comes from conventional generic tablets, not biosimilars.

What generic entry risks exist for IBSRELA?

The near-term risk is driven by the expiration of NCE exclusivity and the possibility of ANDA filings against remaining patents. Generic entry could occur in several forms:

Full-label generic entry

A generic could seek approval for the full IBS-C indication and both approved strengths. This would create the greatest substitution pressure.

Skinny-label entry

A generic could omit a patented method of use if FDA labeling and patent-use requirements allow the applicant to carve out that indication or dosing instruction. Skinny-label entry can still affect market share if pharmacists substitute based on the unpatented indication.

Strength-specific entry

A company could prioritize the 50 mg tablet because it is the commercial default dose, then add the 25 mg strength later. This would leave a partial branded market.

Authorized generic or licensed generic

Ardelyx or a commercial partner could launch an authorized generic to retain some value after patent expiry or to manage Paragraph IV exposure. A licensing or commercialization deal could also give a generic manufacturer early access under settlement terms.

How strong is the IBSRELA patent estate?

The patent estate should be assessed across five dimensions:

Factor	Strategic assessment
Molecule claims	Potentially strongest if valid and unexpired
Use claims	Relevant to IBS-C, constipation, and dose-specific treatment
Formulation claims	Important if they cover measurable dissolution or composition features
Manufacturing claims	Can create supply-chain leverage but may be easier to design around
Regulatory exclusivity	NCE protection has generally expired

The estate is strongest when a patent covers the active ingredient or a broad pharmaceutical composition with a late expiration date. It is weaker when protection depends on narrow excipient ratios, process parameters, or a specific tablet-coating material that a generic can replace without affecting bioequivalence.

For IBSRELA, local gastrointestinal action may make formulation claims commercially meaningful even though systemic pharmacokinetic bioequivalence is not the only relevant development issue. Generic applicants may need to demonstrate comparable dissolution and product performance while managing the possibility that excipient changes affect gastrointestinal tolerability.

What commercial opportunities exist for IBSRELA excipients?

Lactose-free IBSRELA

A lactose-free version could address patients with lactose intolerance or strong preferences for lactose-free medicines. The commercial value is likely incremental rather than transformational because lactose exposure from a tablet is small. The opportunity improves if the product is positioned for patients who attribute bloating or abdominal symptoms to excipients.

Lower-irritancy formulation

Reducing sodium lauryl sulfate or replacing it with another wetting agent could support a tolerability-focused formulation. The developer would need to preserve dissolution, content uniformity, stability, and tablet performance.

Smaller or easier-to-swallow tablet

IBS-C prevalence increases with age, and older patients often use multiple medications. A smaller tablet, orally disintegrating tablet, mini-tablet, or multiparticulate formulation could improve administration. Any alternative dosage form would need to preserve the intended local intestinal exposure and comply with labeling requirements.

Pediatric formulation

IBSRELA is approved for adults. A pediatric development program could create demand for lower strengths, liquid dispersions, granules, or mini-tablets. Pediatric development would also require a favorable safety assessment because diarrhea and dehydration are important risks with tenapanor.[1]

Combination and co-packaging

Commercial opportunities include co-packaging IBSRELA with laxatives, fiber products, or other IBS-C therapies. A fixed-dose combination would face substantial clinical, formulation, and regulatory requirements. A co-packaged regimen would be easier to implement but would provide weaker intellectual-property protection.

Improved packaging

Moisture-protective blister packaging, unit-dose packaging, and adherence-oriented calendar packs could support specialty-pharmacy distribution and reduce handling errors. Packaging claims usually provide limited exclusivity but can improve product differentiation.

How does IBSRELA compare with other IBS-C drugs?

IBSRELA competes primarily with Linzess, Trulance, Amitiza, and generic laxative regimens.

Product	Active ingredient	Mechanism	Main formulation opportunity
IBSRELA	Tenapanor	NHE3 inhibition	Tablet size, lactose-free formulation, pediatric dosage form
Linzess	Linaclotide	Guanylate cyclase-C agonist	Capsule, oral solution, pediatric administration
Trulance	Plecanatide	Guanylate cyclase-C agonist	Tablet or orally dispersible delivery
Amitiza	Lubiprostone	Chloride channel activation	Capsule tolerability and swallowing
OTC laxatives	Multiple	Osmotic, stimulant, or bulk-forming	Low cost, convenience, and combination use

IBSRELA's differentiation is based on mechanism, dosing, and product positioning rather than a highly complex delivery system. The formulation opportunity is therefore most attractive where it improves adherence, tolerability, or access to under-served populations.

What FDA regulatory issues affect new IBSRELA formulations?

A reformulated tenapanor product could require a new drug application, supplemental application, or other regulatory pathway depending on the sponsor, the proposed changes, and the relationship to the approved product.

Key issues include:

• Demonstrating pharmaceutical quality and stability.
• Establishing comparable dissolution.
• Assessing whether excipient changes alter gastrointestinal tolerability.
• Supporting the proposed dosage form and strength.
• Meeting labeling requirements concerning meals and tablet administration.
• Addressing diarrhea, dehydration, and pediatric safety.
• Determining whether the product can rely on existing clinical data.
• Evaluating patent and exclusivity consequences.

An excipient-only change to the marketed product could be handled differently from a new dosage form or a new patient population. The regulatory pathway does not determine patent freedom to operate.

What revenue exposure does IBSRELA create?

IBSRELA is a strategic commercial asset for Ardelyx because it provides branded revenue in a chronic outpatient indication and uses the same tenapanor platform that supports the company's gastrointestinal development strategy. Revenue exposure is concentrated in:

• Continued branded prescription growth.
• Expansion of the diagnosed IBS-C population.
• Payer coverage and prior authorization.
• Persistence relative to competing secretagogues.
• Generic entry after remaining patent barriers expire.
• Potential licensing or regional commercialization agreements.
• New dosage forms and population expansions.

The largest commercial risk is a rapid price-driven erosion after generic entry. The largest excipient-driven opportunity is a differentiated product that improves administration or tolerability without requiring a new mechanism.

Key Takeaways

• IBSRELA is tenapanor, an oral NHE3 inhibitor approved for adult IBS-C.
• The marketed product is a conventional immediate-release film-coated tablet in 25 mg and 50 mg strengths.
• Its excipient system includes lactose, microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, povidone, magnesium stearate, sodium lauryl sulfate, and colloidal silicon dioxide.
• NCE exclusivity generally expired in September 2024; remaining patent protection controls generic timing.
• Biosimilar risk does not apply. The relevant challenge is an ANDA, including potential Paragraph IV litigation.
• The strongest commercial formulation opportunities are lactose-free tablets, lower-irritancy excipient systems, smaller tablets, pediatric dosage forms, and adherence-oriented packaging.
• Standard excipients alone are unlikely to provide strong exclusivity. Protection is more likely to depend on specific compositions, dissolution profiles, manufacturing processes, methods of use, or the tenapanor molecule.
• Generic-entry risk rises materially after NCE expiry, but the timing depends on the current Orange Book patent listing, litigation, and any settlement.
• Commercial value remains tied to IBS-C market penetration, payer access, adherence, and the ability to protect or extend the product beyond the current tablet platform.

FAQs

Can IBSRELA be reformulated without changing its patent risk?

No. A change in excipients can avoid a narrow formulation claim but may remain within broad composition, active-ingredient, or method-of-use claims.

Is a lactose-free IBSRELA likely to receive separate FDA exclusivity?

Usually not solely because lactose is removed. New exclusivity would depend on the regulatory pathway, clinical differentiation, and applicable statutory protections.

Could an IBSRELA generic use different excipients?

Yes, provided the applicant satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and any applicable product-specific guidance.

Would an orally disintegrating tenapanor tablet be commercially attractive?

Potentially. It could address swallowing difficulty and pediatric administration, but development must preserve gastrointestinal performance and manage the drug's diarrhea and dehydration warnings.

Does IBSRELA have biosimilar competition?

No. Tenapanor is a small-molecule active ingredient. Competition would arise through generic drug applications rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2019). IBSRELA (tenapanor) tablets prescribing information. Ardelyx, Inc.

2. U.S. Food and Drug Administration. (2024). Small business and industry assistance: Exclusivity and patent provisions for drug products. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.